Bioinformatic Intern (2027)

Job Description

Job Description

IBRI is poised to transform life sciences—and for millions of people, even life itself.

The Opportunity

The IBRI is seeking students who are interested in bioinformatics, imaging data, and computational biology. Interns will support real research projects while learning from scientists and data professionals. This intern will help analyze high-content imaging data and build tools that make large biological datasets easier to manage and understand.

Program Dates: May 17, 2027 – August 6, 2027

Application Deadline: Applications will be accepted through November 30, 2026. For priority consideration, apply by October 15, 2026.

Schedule: 35 hours per week

Stipend: This internship includes a stipend of $9,650 for the full program, disbursed in bi-weekly installments on or before the 7th and 22nd of each month

Responsibilities

• Support high-content imaging projects and image-based data analysis.
• Help organize and analyze large datasets from cellular images.
• Use Python, R, or similar tools to process data and create summaries.
• Improve documentation so analyses are clear and reproducible.
• Work with research teams to turn data into useful insights.

Qualifications

• High school diploma or equivalent; currently enrolled in a bachelor’s program in bioinformatics, informatics, biology, or a related field.
• Coursework or hands-on experience in bioinformatics, computational biology, or data analysis.
• Programming or scripting experience in Python, R, or similar languages.
• Strong analytical, reasoning, and problem-solving skills.
• Ability to communicate technical concepts clearly to diverse audiences.
• Strong interpersonal skills and ability to work collaboratively in a team environment.
• Interest in bioinformatics, enabling technologies, and pediatric rare disease research.

About Us:

The Indiana Biosciences Research Institute (IBRI) is a first-in-class translational medicine institute dedicated to advancing life sciences in the race to eliminate disease and improve human health and life.

By connecting early-stage biotech companies with cutting-edge life science discoveries —and backed by the mission and resources of industry leaders, investors, and philanthropic partners—IBRI is successfully evolving a new, independent model to conquer disease, uniting previously fragmented forces in the quest for cures.

Carefully curating and supporting early-stage companies with investment, talent, and space, IBRI strategically accelerates drug discovery. Our work benefits from the relatively low cost of living and doing business here, allowing more resources to be directed toward science.

Fueled by the same entrepreneurial creativity as the groundbreaking scientific work we support, IBRI’s labs advance research across the frontiers of diabetes, metabolic disease, Alzheimer’s disease, and rare pediatric diseases. Our ambitious public–private vision cultivates talent while efficiently bridging the gap between research-driven inquiry and profit-driven drug development.

At IBRI, cures are launched on a clear pathway to clinical trials, enabled by the combined resources and experience of our academic and industry partners, without the typical pressure to deliver rapid results for commercialization. IBRI labs pursue breakthroughs that might never happen elsewhere. Breakthroughs are happening here. Our novel financing model ensures that when discoveries are ready for clinical trials, the intellectual property is sold back to industry or spun off, creating a direct stream of revenue.

By every measure, the IBRI model demonstrates a novel approach that delivers rewards. Scientific bench work is nurtured, drug discovery is advanced, workforce development is continuous, investors see returns, and donors see impact. Most importantly, IBRI’s structure and portfolio of accomplishments matter to the patients whose lives are improved—or even saved—by this forward-looking approach to life sciences.

IBRI is driven to bring next-generation therapies to market with an understanding of the complex pressures that often bind innovation to economics. After more than a decade, the evidence is clear: IBRI is poised to transform life sciences—and for millions of people, even life itself.

Equal Employment Opportunity:

The IBRI provides equal employment opportunities to all employees and applicants and does not discriminate based on age, race, color, religion, gender, sexual orientation, gender identity, gender expression, national origin, protected veteran status, disability, or any other legally protected status.